SCHEDULE: Enavate Sciences Reduces CAMP4 Therapeutics Stake to 6.0%

Enavate Sciences GP and Everest Aggregator have reduced their beneficial ownership in CAMP4 Therapeutics Corporation to 6.0% through recent open market sales.

Summary

• Enavate Sciences GP, LLC and Everest Aggregator, LP (the "Reporting Entities") have filed an Amendment No. 2 to their Schedule 13D for CAMP4 Therapeutics Corporation.
• The Reporting Entities now beneficially own an aggregate of 3,127,360 shares of Common Stock, which represents 6.0% of the class.
• This percentage is calculated based on 46,881,134 shares outstanding as of November 3, 2025, plus an additional 5,000,000 shares issued in a public offering that closed on December 19, 2025, totaling 51,881,134 shares.
• Everest Aggregator, LP directly holds the 3,127,360 shares, with Enavate Sciences GP, LLC serving as its general partner and sharing voting and investment authority.
• Between December 16, 2025, and December 23, 2025, Everest Aggregator, LP sold a total of 658,442 shares in open market transactions at weighted average prices ranging from $6.10 to $6.87 per share.

Sentiment

Score: 4

Explanation: The filing indicates a significant shareholder has reduced its stake in CAMP4 Therapeutics Corporation through open market sales, which can be perceived negatively by the market. While the company successfully completed a public offering, which is positive for its capital position, the selling activity by a major holder suggests a cautious outlook from that entity.

Positives

• CAMP4 Therapeutics Corporation successfully completed a public offering of 5,000,000 shares of equity securities, indicating access to capital markets and strengthening its financial position.

Negatives

• The Reporting Entities, significant shareholders, reduced their beneficial ownership by selling 658,442 shares in open market transactions over a short period.
• The sales occurred at prices ranging from $6.05 to $7.20, with weighted average sales prices generally declining towards the end of the selling period (e.g., from $6.65 on December 16, 2025, to $6.10 on December 23, 2025).

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

This filing primarily details changes in beneficial ownership by an investment entity and does not provide sufficient information to analyze broader industry trends or competitors.

Stakeholder Impact

• Shareholders: Existing shareholders may view the reduction in stake by a significant holder as a negative signal, potentially impacting share price. New shareholders from the public offering now have a diluted ownership percentage.
• Company (CAMP4 Therapeutics): The company successfully raised capital through a public offering, which strengthens its financial position.

Key Dates

Recommendation

The filing indicates a significant beneficial owner has substantially reduced its stake in CAMP4 Therapeutics Corporation through open market sales, occurring shortly after the company's public offering. This action by a knowledgeable institutional investor often signals a lack of conviction in the company's near-term prospects or a strategic exit, which could put downward pressure on the stock price. While the company's capital raise is positive for its balance sheet, the selling activity by a major holder suggests caution for potential investors, leading to a 'sell' recommendation.

Keywords

CAMP4 Therapeutics, Enavate Sciences, Everest Aggregator, Schedule 13D, beneficial ownership, equity sales, stock sales, public offering